GLP-1 drugs like semaglutide and liraglutide are revolutionizing diabetes and obesity care by enhancing glucose control and driving weight loss. Their complex manufacturing spanning peptide synthesis, formulation, sterile injectables, and cold-chain logistics poses challenges but also opportunities. With global demand soaring and annual sales projected to exceed $100 billion by 2030, supply chain bottlenecks and device shortages remain critical barriers. As patents for blockb

From tariff shocks to “Buy American” pressures, Trump’s policies tested Indian pharma’s resilience. Yet, in the world’s largest drug...

Ensuring every pharmaceutical label meets CDSCO’s strict standards isn’t optional; it’s the key to patient safety, regulatory approval,...

Ensuring the integrity and excellence of pharmaceutical manufacturing: A comprehensive guide to personnel criteria in maintaining...

Indispensable role that regulatory affairs plays in the pharmaceutical sector and how it ensures that patients receive medications that...

Third-party pharmaceutical manufacturing is no longer a novelty in the pharmaceutical world. With the increasing demand for affordable,...